Nevus  >>  MKC-1106  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MKC-1106 / MannKind
NCT01026051: Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

Terminated
2
5
US
MKC1106-MT
Mannkind Corporation
Stage III Melanoma, Stage IV Melanoma
09/11
07/12
NCT00033228: Vaccine Therapy in Treating Patients With Stage IV Melanoma

Completed
1/2
19
US
MKC1106-MT
Mannkind Corporation
Melanoma (Skin)
03/03
04/03
NCT00688090: Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

Completed
1/2
19
US
Biological: MKC1106-MT, Biological: MKCC1106-MT
Mannkind Corporation
Advanced Melanoma, Stage III and IV Melanoma
12/09
05/10

Download Options